David Lebowitz's Stock Ratings

Citigroup Analyst

David Lebowitz is an analyst at Citigroup. Analyst ratings are quantitative and qualitative analysis of a stock by Wall Street stock rating analysts. Stock ratings consist of expected future growth, current stock valuation and macroeconomic trends. Updated 05/17/2024

Overall Average Return

-5.42%

Smart Score

48.1%

Overall Average Return Percentile

26th

Number of Ratings

55
Buy NowGet Alert
05/10/2024NTLABuy Now
Intellia Therapeutics
$25.7812.49%$31 → $29MaintainsNeutralGet Alert
05/07/2024PLRXBuy Now
Pliant Therapeutics
$15.27188.15%$45 → $44MaintainsBuyGet Alert
05/03/2024BPMCBuy Now
Blueprint Medicines
$104.96-27.59%$65 → $76MaintainsSellGet Alert
05/02/2024SDGRBuy Now
Schrodinger
$22.5364.19%$39 → $37MaintainsBuyGet Alert
03/06/2024MDGLBuy Now
Madrigal Pharmaceuticals
$220.0673.59% → $382Initiates → BuyGet Alert
03/01/2024SDGRBuy Now
Schrodinger
$22.5373.07%$47 → $39MaintainsBuyGet Alert
02/29/2024SDGRBuy Now
Schrodinger
$22.5373.07%$47 → $39MaintainsBuyGet Alert
02/26/2024COGTBuy Now
Cogent Biosciences
$7.4474.73%$11 → $13MaintainsBuyGet Alert
02/23/2024BBIOBuy Now
BridgeBio Pharma
$30.1152.77%$42 → $46MaintainsBuyGet Alert
02/16/2024BPMCBuy Now
Blueprint Medicines
$104.96-38.07%$54 → $65MaintainsSellGet Alert
02/14/2024INCYBuy Now
Incyte
$57.1441.76%$82 → $81MaintainsBuyGet Alert
02/08/2024ASNDBuy Now
Ascendis Pharma
$121.1250.26%$146 → $182MaintainsBuyGet Alert
02/08/2024COGTBuy Now
Cogent Biosciences
$7.4447.85% → $11Initiates → BuyGet Alert
12/15/2023EXELBuy Now
Exelixis
$20.9148.25% → $31Initiates → BuyGet Alert
11/07/2023BBIOBuy Now
BridgeBio Pharma
$30.1139.49% → $42Initiates → BuyGet Alert
07/31/2023IONSBuy Now
Ionis Pharmaceuticals
$37.3160.81%$36 → $60UpgradeNeutral → BuyGet Alert
07/25/2023INCYBuy Now
Incyte
$57.1443.51% → $82Initiates → BuyGet Alert
06/30/2023BMRNBuy Now
Biomarin Pharmaceutical
$77.5623.78%$103 → $96MaintainsNeutralGet Alert
05/08/2023SDGRBuy Now
Schrodinger
$22.53121.88%$52 → $50MaintainsBuyGet Alert
05/04/2023IONSBuy Now
Ionis Pharmaceuticals
$37.31-3.51%$30 → $36UpgradeSell → NeutralGet Alert
04/27/2023BMRNBuy Now
Biomarin Pharmaceutical
$77.5632.8%$114 → $103MaintainsNeutralGet Alert
04/05/2023ASNDBuy Now
Ascendis Pharma
$121.1220.54%$163 → $146MaintainsBuyGet Alert
03/13/2023PLRXBuy Now
Pliant Therapeutics
$15.27227.44%$55 → $50MaintainsBuyGet Alert
02/21/2023BMRNBuy Now
Biomarin Pharmaceutical
$77.5649.56% → $116Initiates → NeutralGet Alert
01/31/2023SDGRBuy Now
Schrodinger
$22.53126.32%$48 → $51MaintainsBuyGet Alert
01/24/2023NTLABuy Now
Intellia Therapeutics
$25.7851.28%$48 → $39UpgradeSell → NeutralGet Alert
01/24/2023PLRXBuy Now
Pliant Therapeutics
$15.27260.18%$36 → $55MaintainsBuyGet Alert
11/10/2022MIRMBuy Now
Mirum Pharmaceuticals
$24.0741.25%$38 → $34MaintainsBuyGet Alert
11/10/2022IONSBuy Now
Ionis Pharmaceuticals
$37.31-16.91%$28 → $31MaintainsSellGet Alert
11/03/2022ASNDBuy Now
Ascendis Pharma
$121.1234.58%$157 → $163MaintainsBuyGet Alert

Recent Analyst Stock Rating News

Unveiling 18 Analyst Insights On Blueprint Medicines
The Analyst Verdict: Blueprint Medicines In The Eyes Of 7 Experts
Peeling Back The Layers: Exploring Incyte Through Analyst Insights
Decoding 6 Analyst Evaluations For Blueprint Medicines
Incyte Stock: A Deep Dive Into Analyst Perspectives (8 Ratings)
Critical Insights From Schrodinger Analyst Ratings: What You Need To Know
Breaking Down Exelixis: 7 Analysts Share Their Views
Rare Disease Player BridgeBio Pharma's Upside Potential Is Significant According to Citi Analyst - Here's Why
Citi initiated coverage on BridgeBio Pharma Inc (NASDAQ: BBIO), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, noting an optimistic outlook on the stock.
From LTCM To 1966. The Perils Of Rising Interest Rates
By Michael Lebowitz
Analyst Upgrades Ionis Pharmaceuticals To Buy Amid Key Pipeline Developments: Eplontersen And Donidalorsen Show Promising Outlook
Citi analyst upgraded Ionis Pharmaceuticals Inc (NASDAQ: IONS) from Neutral to Buy with a price target of $60, increased from $36, citing multiple key 
The Best Trading Research Platform
For Retail Investors and Professional Trades Alike.
Get Started for Free